

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**CanSino Biologics Inc.**  
**康希諾生物股份公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 6185)**

**PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION  
AND THE RULES OF PROCEDURES**

CanSino Biologics Inc. (the “**Company**”) held the eleventh meeting of the third session of the board (the “**Board**”) of directors (the “**Directors**”) on April 28, 2026, to consider and approve, among other things, the proposed amendments to the articles of association of the Company (the “**Articles of Association**”) and the rules of procedure for the general meeting of the shareholders of the Company (the “**Shareholders**”) and the rules of procedure of the Board of Directors (collectively, the “**Rules of Procedures**”).

To further enhance the Company’s standards of corporate governance and operational compliance, and in accordance with the latest provisions of the Company Law of the People’s Republic of China, the Rules for Corporate Governance of Listed Companies, together with other relevant laws, administrative regulations and normative documents, the Board proposed to amend the Articles of Association and the Rules of Procedures. Key amendments include (i) refining the arrangements for proxy solicitation of Shareholders’ rights and the triggers for cumulative voting in the election of Directors; (ii) strengthening governance and compliance obligations for Directors and senior management, including cessation/removal procedures upon disqualification, competing business disclosure duties, and the duty of care in Board deliberations; and (iii) enhancing the post-departure accountability framework for Directors and the procedural requirements for convening urgent Board meetings.

The proposed amendments to the Articles of Association and the Rules of Procedures are subject to the approval of the Shareholders at the upcoming annual general meeting by way of special resolutions. A circular of the Company containing, among other things, detailed information on the proposed amendments to the Articles of Association and the Rules of Procedures will be despatched to the Shareholders in due course.

By order of the Board  
**CanSino Biologics Inc.**  
**Xuefeng YU**  
*Chairman*

Hong Kong, April 28, 2026

*As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO and Ms. Jing WANG as executive Directors, Mr. Chi Shing LI as a non-executive Director, and Mr. Yiu Leung Andy CHEUNG, Mr. Man CHO and Ms. Xuefeng JI as independent non-executive Directors.*